ClinicaliQ Trial Snapshot
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. — Recruiting • Phase II • Oncology • NCT07440290.
- Treatment Being Tested: The combination of dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) in patients with BRAF V600 mutation-positive cancers across multiple cancer types including melanoma, lung cancer, and glioma.
- Patient Eligibility Overview: Adult, paediatric, and teenage/young adult patients with confirmed BRAF V600 mutation-positive cancers; eligibility extends across multiple tumour types (melanoma, lung cancer, glioma) representing a broad patient population.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in children with glioma (a type of brain tumour). This means they have gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Dabrafenib and trametinib work in patients with a particular mutation in their cancer known as BRAF V600. Investigators now wish to find…
Eligibility Snapshot
- THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL (NCT05722886) AND WITHIN THE TREATMENT ARM 07 (DABRAFENIB AND TRAMETINIB) OUTLINED BELOW* *When dabrafenib- and trametinib-specific inclusion/
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.